Illumina (ILMN)

• Illumina jumped to a 20-month high and is under heavy accumulation

Illumina (NASDAQ: ILMN) — This company develops, manufactures and markets life science tools and integrated systems for the analysis of genetic variation and biological function.

Credit Suisse raised its price target to $72 from $59 after the company reported first-quarter earnings of $0.46 versus a consensus estimate of $0.38. The Credit Suisse analyst said, “We reiterate our outperform rating and consider ILMN our top pick.”

Technically, the stock is in a powerful bull trend and recently broke to new highs on a breakaway gap from a bullish “W” pattern. On Thursday, it jumped to a 20-month high and is under heavy accumulation. Its short-term trading target is $70, but longer term look for $72-$80.